CHAMPIONS ONCOLOGY, INC.
CSBRNasdaqHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $56.9M | $50.2M | $53.9M | $49.1M | $41.0M | $32.1M |
| Operating income | $4.6M | −$7.4M | −$5.3M | $607,000 | $366,000 | −$1.9M |
| Net income | $4.7M | −$7.3M | −$5.3M | $548,000 | $362,000 | −$2.1M |
| Total assets | $32.3M | $26.1M | $34.3M | $35.4M | $27.6M | $20.8M |
| Total liabilities | $28.6M | $28.0M | $29.7M | $26.3M | $20.2M | $15.7M |
| Equity | $3.8M | −$1.9M | $4.6M | $9.1M | $7.4M | $5.1M |
| EPS (diluted) | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 |
| Shares out. | 13.8M | 13.6M | 13.5M | 13.5M | 13.4M | 12726.73B |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 8.0%
- Net margin
- 8.3%
- Return on equity
- 124.6%
- Return on assets
- 14.5%
- Return on capital (ROCE)
- 53.6%
- Liabilities / assets
- 88.3%
- Debt / equity
- 7.57×
- Book value / share
- $0.27
- Revenue growth (YoY)
- 13.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -7.27distress
- Accruals / assets
- −8.3%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 1 warning● 5 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Jul 30, 2009
- NT 10-Kmissed a reporting deadline ↗Jul 27, 2007
- NT 10-Qmissed a reporting deadline ↗Mar 17, 2006
- NT 10-Kmissed a reporting deadline ↗Jul 29, 2005
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Tocqueville Asset Management L.P.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ackerman JoelDirector | Oct 30, 2025 | Option exercise | 94,405 | $2.10 |
| Breitfeld Philip P.Director | Mar 25, 2025 | J | 4,150 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 84,726 | 7.6 | +1.2% |
| Apr 30, 2026 | 83,705 | 13.4 | +2.1% |
| Apr 15, 2026 | 81,985 | 10.8 | +0.1% |
| Mar 31, 2026 | 81,893 | 7.4 | +12.8% |
| Mar 13, 2026 | 72,630 | 9.9 | +4.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer changeMar 30, 2026
- Results of operationsMar 12, 2026
- Results of operationsDec 15, 2025
- Shareholder voteOct 16, 2025
- Results of operationsSep 15, 2025
- Results of operationsJul 23, 2025
- Results of operationsMar 11, 2025
- Results of operationsDec 11, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.